Calliditas Therapeutics AB (FRA:LC8)
€ 17.83 0.06 (0.34%) Market Cap: 963.42 Mil Enterprise Value: 981.96 Mil PE Ratio: 0 PB Ratio: 104.30 GF Score: 51/100

Calliditas Therapeutics AB Nefigard Topline Data Presentation Transcript

Mar 13, 2023 / 12:00PM GMT
Release Date Price: €10.29 (+26.88%)

Mar 13, 2023 / 12:00PM GMT
Presentation
Mar 13, 2023 / 12:00PM GMT

=====================
Corporate Participants
=====================
* Andrew B. Udell
Calliditas Therapeutics AB (publ) - President of North America Commercial
* Jonathan Barratt
* Renee Aguiar-Lucander
Calliditas Therapeutics AB (publ) - CEO
* Richard S. Philipson
Calliditas Therapeutics AB (publ) - Chief Medical Officer

=====================
Conference Call Participants
=====================
* Annabel Eva Samimy
Stifel, Nicolaus & Company, Incorporated, Research Division - MD
* Dan Akschuti
Pareto Securities AS, Research Division - Research Analyst
* Ingird Gafanhão
Bryan Garnier & Co Ltd, Research Division - Research Analyst
* Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
* Rami Azeez Katkhuda
LifeSci Capital, LLC, Research Division - Research Analyst
* Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

=====================

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot